The National Association of Pharmacy Regulatory Authorities has finalized its recommendations on on brimonidine tartrate ophthalmic solution in concentrations up to and Including 0.025%.
The organization's annual report for 2021, Navigating a World in Transition, covers the key moves for last year, as well as what's coming up in the rest of 2022.
